Asset Management
Compare Stocks
5 / 10Stock Comparison
INV vs GCBC vs XOMA vs CZWI vs NECB
Revenue, margins, valuation, and 5-year total return — side by side.
Banks - Regional
Biotechnology
Banks - Regional
Banks - Regional
INV vs GCBC vs XOMA vs CZWI vs NECB — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Asset Management | Banks - Regional | Biotechnology | Banks - Regional | Banks - Regional |
| Market Cap | $349M | $408M | $490M | $203M | $339M |
| Revenue (TTM) | $1M | $133M | $52M | $90M | $157M |
| Net Income (TTM) | $-317M | $37M | $29M | $14M | $44M |
| Gross Margin | -271.2% | 55.7% | 94.3% | 54.7% | 66.1% |
| Operating Margin | -63.2% | 26.1% | 21.8% | 7.0% | 39.6% |
| Forward P/E | — | 13.1x | 36.7x | 11.8x | 7.8x |
| Total Debt | $28M | $128M | $132M | $52M | $75M |
| Cash & Equiv. | $11M | $185M | $83M | $119M | $81M |
INV vs GCBC vs XOMA vs CZWI vs NECB — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Nov 21 | May 26 | Return |
|---|---|---|---|
| Innventure, Inc. (INV) | 100 | 70.0 | -30.0% |
| Greene County Banco… (GCBC) | 100 | 141.2 | +41.2% |
| XOMA Royalty Corp. (XOMA) | 100 | 204.2 | +104.2% |
| Citizens Community … (CZWI) | 100 | 155.9 | +55.9% |
| Northeast Community… (NECB) | 100 | 221.4 | +121.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: INV vs GCBC vs XOMA vs CZWI vs NECB
Each card shows where this stock fits in a portfolio — not just who wins on paper.
INV lags the leaders in this set but could rank higher in a more targeted comparison.
Among these 5 stocks, GCBC doesn't own a clear edge in any measured category.
XOMA carries the broadest edge in this set and is the clearest fit for growth exposure.
- Rev growth 83.1%, EPS growth 188.5%, 3Y rev CAGR 105.3%
- 83.1% revenue growth vs CZWI's -9.4%
- 56.4% margin vs INV's -64.1%
- +68.7% vs NECB's +10.7%
CZWI ranks third and is worth considering specifically for income & stability and sleep-well-at-night.
- Dividend streak 7 yrs, beta 0.46, yield 1.8%
- Lower volatility, beta 0.46, Low D/E 27.6%, current ratio 3015.31x
- Beta 0.46, yield 1.8%, current ratio 3015.31x
- Beta 0.46 vs INV's 2.63
NECB is the #2 pick in this set and the best alternative if long-term compounding and valuation efficiency is your priority.
- 460.8% 10Y total return vs GCBC's 198.9%
- PEG 0.23 vs XOMA's 2.75
- NIM 4.9% vs GCBC's 2.0%
- Lower P/E (7.8x vs 11.8x), PEG 0.23 vs 2.32
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 83.1% revenue growth vs CZWI's -9.4% | |
| Value | Lower P/E (7.8x vs 11.8x), PEG 0.23 vs 2.32 | |
| Quality / Margins | 56.4% margin vs INV's -64.1% | |
| Stability / Safety | Beta 0.46 vs INV's 2.63 | |
| Dividends | 4.0% yield, 2-year raise streak, vs CZWI's 1.8% | |
| Momentum (1Y) | +68.7% vs NECB's +10.7% | |
| Efficiency (ROA) | 12.1% ROA vs INV's -47.4%, ROIC 7.4% vs -14.8% |
INV vs GCBC vs XOMA vs CZWI vs NECB — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
Segment breakdown not available.
INV vs GCBC vs XOMA vs CZWI vs NECB — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
XOMA leads in 2 of 6 categories
NECB leads 1 • INV leads 0 • GCBC leads 0 • CZWI leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
XOMA leads this category, winning 3 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
NECB is the larger business by revenue, generating $157M annually — 129.0x INV's $1M. XOMA is the more profitable business, keeping 56.4% of every revenue dollar as net income compared to INV's -64.1%.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $1M | $133M | $52M | $90M | $157M |
| EBITDAEarnings before interest/tax | -$451M | $42M | $14M | $9M | $63M |
| Net IncomeAfter-tax profit | -$317M | $37M | $29M | $14M | $44M |
| Free Cash FlowCash after capex | -$87M | $33M | $3M | $11M | $51M |
| Gross MarginGross profit ÷ Revenue | -2.7% | +55.7% | +94.3% | +54.7% | +66.1% |
| Operating MarginEBIT ÷ Revenue | -63.2% | +26.1% | +21.8% | +7.0% | +39.6% |
| Net MarginNet income ÷ Revenue | -64.1% | +23.4% | +56.4% | +16.0% | +28.2% |
| FCF MarginFCF ÷ Revenue | -40.2% | +20.5% | +5.4% | +11.5% | +32.3% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — | +57.9% | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | -9.3% | +36.4% | +157.8% | +63.0% | +6.8% |
Valuation Metrics
NECB leads this category, winning 5 of 7 comparable metrics.
Valuation Metrics
At 7.5x trailing earnings, NECB trades at a 73% valuation discount to XOMA's 28.3x P/E. Adjusting for growth (PEG ratio), NECB offers better value at 0.22x vs CZWI's 2.85x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $349M | $408M | $490M | $203M | $339M |
| Enterprise ValueMkt cap + debt − cash | $366M | $352M | $538M | $136M | $333M |
| Trailing P/EPrice ÷ TTM EPS | -3.55x | 13.11x | 28.28x | 14.44x | 7.54x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 36.74x | 11.76x | 7.81x |
| PEG RatioP/E ÷ EPS growth rate | — | 1.22x | 2.12x | 2.85x | 0.22x |
| EV / EBITDAEnterprise value multiple | — | 9.85x | 37.50x | 15.28x | 5.25x |
| Price / SalesMarket cap ÷ Revenue | 286.17x | 3.07x | 9.39x | 2.25x | 2.15x |
| Price / BookPrice ÷ Book value/share | 0.36x | 1.71x | 8.85x | 1.09x | 0.95x |
| Price / FCFMarket cap ÷ FCF | — | 14.97x | 170.55x | 19.55x | 6.67x |
Profitability & Efficiency
XOMA leads this category, winning 3 of 9 comparable metrics.
Profitability & Efficiency
XOMA delivers a 31.9% return on equity — every $100 of shareholder capital generates $32 in annual profit, vs $-59 for INV. INV carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to XOMA's 1.57x. On the Piotroski fundamental quality scale (0–9), GCBC scores 7/9 vs INV's 3/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -58.9% | +15.0% | +31.9% | +7.8% | +13.1% |
| ROA (TTM)Return on assets | -47.4% | +1.2% | +12.1% | +0.8% | +2.2% |
| ROICReturn on invested capital | -14.8% | +6.7% | +7.4% | +2.0% | +12.5% |
| ROCEReturn on capital employed | -18.1% | +10.7% | +5.2% | +0.6% | +16.2% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 7 | 5 | 6 | 5 |
| Debt / EquityFinancial leverage | 0.04x | 0.54x | 1.57x | 0.28x | 0.21x |
| Net DebtTotal debt minus cash | $17M | -$56M | $49M | -$67M | -$6M |
| Cash & Equiv.Liquid assets | $11M | $185M | $83M | $119M | $81M |
| Total DebtShort + long-term debt | $28M | $128M | $132M | $52M | $75M |
| Interest CoverageEBIT ÷ Interest expense | -57.53x | 0.74x | 2.90x | 0.16x | 1.17x |
Total Returns (Dividends Reinvested)
Evenly matched — XOMA and CZWI and NECB each lead in 2 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in NECB five years ago would be worth $22,024 today (with dividends reinvested), compared to $6,210 for INV. Over the past 12 months, XOMA leads with a +68.7% total return vs NECB's +10.7%. The 3-year compound annual growth rate (CAGR) favors CZWI at 37.5% vs INV's -15.7% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +38.6% | +10.7% | +47.5% | +21.5% | +9.4% |
| 1-Year ReturnPast 12 months | +59.2% | +10.9% | +68.7% | +45.6% | +10.7% |
| 3-Year ReturnCumulative with dividends | -40.0% | +37.1% | +126.1% | +160.0% | +107.8% |
| 5-Year ReturnCumulative with dividends | -37.9% | +97.6% | +30.0% | +71.2% | +120.2% |
| 10-Year ReturnCumulative with dividends | -37.9% | +198.9% | +186.7% | +157.0% | +460.8% |
| CAGR (3Y)Annualised 3-year return | -15.7% | +11.1% | +31.3% | +37.5% | +27.6% |
Risk & Volatility
Evenly matched — XOMA and CZWI each lead in 1 of 2 comparable metrics.
Risk & Volatility
CZWI is the less volatile stock with a 0.46 beta — it tends to amplify market swings less than INV's 2.63 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. XOMA currently trades 96.4% from its 52-week high vs INV's 83.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.81x | 0.84x | 1.16x | 0.45x | 0.81x |
| 52-Week HighHighest price in past year | $7.45 | $26.04 | $42.81 | $22.62 | $25.61 |
| 52-Week LowLowest price in past year | $2.36 | $21.16 | $22.29 | $12.83 | $19.27 |
| % of 52W HighCurrent price vs 52-week peak | +83.4% | +92.1% | +96.4% | +93.2% | +95.7% |
| RSI (14)Momentum oscillator 0–100 | 66.0 | 55.9 | 71.1 | 63.7 | 50.5 |
| Avg Volume (50D)Average daily shares traded | 1.9M | 12K | 242K | 40K | 36K |
Analyst Outlook
Evenly matched — CZWI and NECB each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: XOMA as "Buy", CZWI as "Buy", NECB as "Hold". Consensus price targets imply 30.2% upside for XOMA (target: $54) vs 28.8% for INV (target: $8). For income investors, NECB offers the higher dividend yield at 3.98% vs INV's 0.24%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — | Buy | Buy | Hold |
| Price TargetConsensus 12-month target | $8.00 | — | $53.75 | — | — |
| # AnalystsCovering analysts | — | — | 10 | 2 | 1 |
| Dividend YieldAnnual dividend ÷ price | +0.2% | +1.1% | +0.7% | +1.8% | +4.0% |
| Dividend StreakConsecutive years of raises | 1 | 2 | 0 | 7 | 2 |
| Dividend / ShareAnnual DPS | $0.01 | $0.26 | $0.30 | $0.37 | $0.98 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +3.3% | +3.1% | +0.5% |
XOMA leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). NECB leads in 1 (Valuation Metrics). 3 tied.
INV vs GCBC vs XOMA vs CZWI vs NECB: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is INV or GCBC or XOMA or CZWI or NECB a better buy right now?
For growth investors, XOMA Royalty Corp.
(XOMA) is the stronger pick with 83. 1% revenue growth year-over-year, versus -9. 4% for Citizens Community Bancorp, Inc. (CZWI). Northeast Community Bancorp, Inc. (NECB) offers the better valuation at 7. 5x trailing P/E (7. 8x forward), making it the more compelling value choice. Analysts rate XOMA Royalty Corp. (XOMA) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — INV or GCBC or XOMA or CZWI or NECB?
On trailing P/E, Northeast Community Bancorp, Inc.
(NECB) is the cheapest at 7. 5x versus XOMA Royalty Corp. at 28. 3x. On forward P/E, Northeast Community Bancorp, Inc. is actually cheaper at 7. 8x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Northeast Community Bancorp, Inc. wins at 0. 23x versus XOMA Royalty Corp. 's 2. 75x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — INV or GCBC or XOMA or CZWI or NECB?
Over the past 5 years, Northeast Community Bancorp, Inc.
(NECB) delivered a total return of +120. 2%, compared to -37. 9% for Innventure, Inc. (INV). Over 10 years, the gap is even starker: NECB returned +459. 8% versus INV's -30. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — INV or GCBC or XOMA or CZWI or NECB?
By beta (market sensitivity over 5 years), Citizens Community Bancorp, Inc.
(CZWI) is the lower-risk stock at 0. 45β versus Innventure, Inc. 's 2. 81β — meaning INV is approximately 519% more volatile than CZWI relative to the S&P 500. On balance sheet safety, Innventure, Inc. (INV) carries a lower debt/equity ratio of 4% versus 157% for XOMA Royalty Corp. — giving it more financial flexibility in a downturn.
05Which is growing faster — INV or GCBC or XOMA or CZWI or NECB?
By revenue growth (latest reported year), XOMA Royalty Corp.
(XOMA) is pulling ahead at 83. 1% versus -9. 4% for Citizens Community Bancorp, Inc. (CZWI). On earnings-per-share growth, the picture is similar: XOMA Royalty Corp. grew EPS 188. 5% year-over-year, compared to -143. 1% for Innventure, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — INV or GCBC or XOMA or CZWI or NECB?
XOMA Royalty Corp.
(XOMA) is the more profitable company, earning 60. 8% net margin versus -64. 1% for Innventure, Inc. — meaning it keeps 60. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NECB leads at 39. 6% versus -63. 2% for INV. At the gross margin level — before operating expenses — XOMA leads at 94. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is INV or GCBC or XOMA or CZWI or NECB more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Northeast Community Bancorp, Inc. (NECB) is the more undervalued stock at a PEG of 0. 23x versus XOMA Royalty Corp. 's 2. 75x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Northeast Community Bancorp, Inc. (NECB) trades at 7. 8x forward P/E versus 36. 7x for XOMA Royalty Corp. — 28. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for XOMA: 30. 2% to $53. 75.
08Which pays a better dividend — INV or GCBC or XOMA or CZWI or NECB?
All stocks in this comparison pay dividends.
Northeast Community Bancorp, Inc. (NECB) offers the highest yield at 4. 0%, versus 0. 2% for Innventure, Inc. (INV).
09Is INV or GCBC or XOMA or CZWI or NECB better for a retirement portfolio?
For long-horizon retirement investors, Citizens Community Bancorp, Inc.
(CZWI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 45), 1. 8% yield, +161. 7% 10Y return). Innventure, Inc. (INV) carries a higher beta of 2. 81 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CZWI: +161. 7%, INV: -30. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between INV and GCBC and XOMA and CZWI and NECB?
These companies operate in different sectors (INV (Financial Services) and GCBC (Financial Services) and XOMA (Healthcare) and CZWI (Financial Services) and NECB (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: INV is a small-cap quality compounder stock; GCBC is a small-cap deep-value stock; XOMA is a small-cap high-growth stock; CZWI is a small-cap deep-value stock; NECB is a small-cap deep-value stock. GCBC, XOMA, CZWI, NECB pay a dividend while INV does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.